Please login to the form below
Kesimpta
This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.
Novartis announces positive long-term data for relapsing MS treatment Kesimpta
Novartis has announced positive new long-term data from an open-label extension study of its multiple sclerosis (MS) treatment, Kesimpta (ofatumumab). ... versus those who started on disease modifying therapy (Aubagio) teriflunomide and were later
Latest news
-
Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients
Kesimpta is the first subcutaneous B-cell therapy that can be self-administered at home for people with RRMS. ... The overall fatal outcome (0.8%) and hospitalisation rates (9.4%) due to COVID-19 in Kesimpta-treated patients were lower than the rates
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
Rejuvenation of our portfolio continues, from our key brands which include Kesimpta, Leqvio, Zolgensma and the oncology portfolio,” said Novartis CEO Vas Narasimhan.
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab). ... Both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and
-
Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
Kesimpta was approved in the EU for the treatment of RMS in adults with active disease at the end of March. ... Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study.
More from news
Approximately 5 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
